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RESEARCH NOTE
Prediction of opioid dose in cancer pain 
patients using genetic profiling: not yet an 
option with support vector machine learning
Anne Estrup Olesen1,2,3, Debbie Grønlund1,3, Mikkel Gram1, Frank Skorpen4, Asbjørn Mohr Drewes1,3 
and Pål Klepstad5,6,7*
Abstract 
Objective: Use of opioids for pain management has increased over the past decade; however, inadequate analgesic 
response is common. Genetic variability may be related to opioid efficacy, but due to the many possible combina-
tions and variables, statistical computations may be difficult. This study investigated whether data processing with 
support vector machine learning could predict required opioid dose in cancer pain patients, using genetic profil-
ing. Eighteen single nucleotide polymorphisms (SNPs) within the µ and δ opioid receptor genes and the catechol-
O-methyltransferase gene were selected for analysis.
Results: Data from 1237 cancer pain patients were included in the analysis. Support vector machine learning did not 
find any associations between the assessed SNPs and opioid dose in cancer pain patients, and hence, did not provide 
additional information regarding prediction of required opioid dose using genetic profiling.
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Introduction
Opioids are the basis in treatment of severe pain of both 
benign and malignant origin. Unfortunately, the clinical 
use is limited by large inter-individual differences in anal-
gesic responses, and insufficient treatment is often seen. 
Unacceptable side effects may also appear, potentially 
reducing quality of life. Thus, identification of biomark-
ers that can predict the appropriate opioid type and dose 
for the individual patient is highly warranted. Currently, 
there is no well-validated objective means of identifying 
patients likely to experience adequate opioid analgesia, 
and quantitative sensory testing as well as clinical bio-
markers have been applied with low success [1–3].
Various factors such as gender, age, and genetic varia-
tion may influence the analgesic response to opioids. Sev-
eral single nucleotide polymorphisms (SNPs) in different 
candidate genes have been demonstrated to be associated 
with altered pain sensitivity and analgesic response [4]. 
The genetic variations can influence the pharmacokinet-
ics and/or pharmacodynamics of opioids and potentially 
the effect. A large study, the European Pharmacogenetic 
Opioid Study (EPOS) included 2294 cancer pain patients 
and investigated the influence of genetic variability on 
multiple pain-related outcomes and required opioid dose 
[5, 6]. No significant associations were found between 
112 SNPs in 25 candidate genes and opioid dose, thus 
the findings did not support the use of genetics profiling 
to guide opioid treatment. However, statistical analysis 
including multiple testing of several factors may be a lim-
itation. In contrast, machine learning can include many 
factors in a single analysis, limiting the risk of erroneous 
false-positive results [7]. Support vector machine (SVM) 
is a data driven method, which enables detection of sub-
tle patterns in complex datasets, which are only visible 
when assessing multiple variables at once. This could be 
the case for genetic data, where certain combinations of 
genes could determine the effect.
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The objective of the present study was to use SVM 
analysis of various SNPs to predict the required opioid 
dose in cancer pain patients.
Main text
Methods
Study design and patient samples
Data from the EPOS study was used for analysis [6]. 
In brief, the study included patients from 17 cen-
tres in 11 European countries. Inclusion criteria were: 
age > 18 years; diagnosed with a malignant disease; using 
opioids for moderate to severe pain; treated with regu-
lar oral, subcutaneous, transdermal or intravenous opi-
oids (morphine, methadone, fentanyl, hydromorphone, 
buprenorphine, or oxycodone) for a minimum of 3 days.
Study outcome
The median oral morphine equivalent dose in the full 
population of 2294 patients was 180 mg/24 h. Therefore, 
patients were divided into two groups: Group 1 requir-
ing less or equal to 180 mg/24 h; group 2 requiring more 
than 180 mg/24 h.
Gene selection and genotyping
In the present study, nineteen SNPs; nine SNPs in the 
OPRM1 gene, one in OPRK1, three in OPRD1 and six 
in COMT, were selected as relevant. The SNPs were 
selected according to previous studies, in which genetic 
associations to opioid analgesic effects were found [4, 
8, 9]. The genotype distributions are listed in Table  1. 
As minor allele frequency had to be higher than 10% to 
be included in data analysis, the OPRK1 was discarded. 
SNPs were coded to be binary variables for inclusion in 
the SVM, hence, they were coded so that carriage of the 
minor allele equals 1 and homozygous for the major allele 
equals 0 in the model.
Machine learning analysis
SVM is a binary classifier, previously used in other predic-
tion studies in pain medicine [10, 11]. In the present study, 
classification was performed using the libSVM toolbox 
(version 3.20) for Matlab [11], and a linear kernel function 
was used to avoid over-fitting of the model [12]. The analy-
sis process is described in details elsewhere [13]. In brief, 
10 features along with a label indicating to which opioid 
dose group the patient belonged to were analyzed in the 
SVM. The number of features was determined by calcu-
lating the accuracy of the classifier by gradually increas-
ing the number of features up to 10. Accuracy was defined 
as the ratio between correctly classified subjects and total 
number of subjects in percentage. Based on this, the SVM 
calculated an optimal decision rule to separate the two 
Table 1 Genotype distribution in the study population
Gene dbSNP Geno-
type
Fre-
quency
Percent-
age
Cumulative
OPRD1 rs533123 CC 74 3.45 3.45
CT 695 32.45 35.9
TT 1373 64.1 100
Total 2142 100
rs678849 CC 480 22.13 22.13
CT 1009 46.52 68.65
TT 680 31.35 100
Total 2169 100
rs2236857 AA 676 52.65 52.65
AG 509 39.64 92.29
GG 99 7.71 100
Total 1284 100
OPRM1 rs1799971 AA 1363 76.44 76.44
AG 393 22.04 98.48
GG 27 1.51 99.99
Total 1783 100
rs540825 AA 1234 56.07 56.07
AT 821 37.3 93.37
TT 146 6.63 100
Total 2201 100
rs562859 AA 950 43.58 43.58
AG 962 44.13 87.71
GG 268 12.29 100
Total 2180 100
rs548646 CC 918 42.68 42.68
CT 965 44.86 87.54
TT 268 12.46 100
Total 2151 100
rs1323042 AA 590 27.05 27.05
AC 1083 49.66 76.71
CC 508 23.29 100
Total 2181 100
rs618207 CC 956 43.51 43.51
CT 974 44.33 87.84
TT 267 12.15 99.99
Total 2197 100
rs639855 GG 1247 56.81 56.81
GT 806 36.72 93.53
TT 142 6.47 100
Total 2195 100
rs9479757 AA 20 0.91 0.91
AG 369 16.8 17.71
GG 1807 82.29 100
Total 2196 100
rs497976 AA 142 6.49 6.49
AC 804 36.75 43.24
CC 1242 56.76 100
Total 2188 100
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groups in the most optimal way. This was done by leave-
one-out cross-validation by extracting one patient for test-
ing, and using the remaining patients to train the model. 
This process was repeated until all patients had been left 
out. Once a decision rule was determined, a classification 
accuracy for each of the 10 features was calculated.
Statistical analysis
The null hypothesis was that SVM analysis of various 
SNPs could not predict the required opioid dose in can-
cer pain patients. All data are reported as mean ± stand-
ard deviation. Results from SVM classification were 
analyzed using Chi square tests. P values below 0.05 were 
considered statistically significant.
Results
Out of 2294 EPOS participants, 1057 were excluded 
due to missing one or several of the selected SNPs. The 
included 1237 patients (637 males and 600 females) had 
an age of 62.6 ±  12.3  years and BMI of 23.4 ±  4.6). Of 
these, 662 (53%) required less or equal to 180  mg/24  h 
oral morphine equivalents, and 575 (47%) required more 
than 180 mg/24 h.
Machine learning was unable to distinguish between 
patients requiring less or equal to 180 mg/24 h oral mor-
phine equivalents and those requiring more, using any 
number of SNP features from 1 to 10. Classification accu-
racies were: 1 feature; 52.9% (P = 0.08), 2 features; 52.9% 
(P = 0.08), 3 features; 52.9% (P = 0.08), 4 features; 52.9% 
(P = 0.08), 5 features; 52.9% (P = 0.08), 6 features; 53.0% 
(P = 0.07), 7 features; 53.0% (P = 0.07), 8 features; 53.0% 
(P = 0.07), 9 features; 53.0% (P = 0.07) and 10 features; 
52.8% (P = 0.08).
Discussion
This study aimed to investigate whether SVM was able 
to identify associations between genetic variability and 
required opioid dose in cancer pain patients. None of 
the chosen 18 SNPs in the three candidate genes showed 
significant association with opioid dose, which support 
earlier findings from the EPOS study in which regular 
linear regressions were unable to identify correlations [6]. 
Hence, SVM analysis did not provide additional informa-
tion regarding prediction of opioid dose using genetic 
profiling.
Limitations
A single SNP may only explain a minor part of analge-
sic variability. A recent study showed that combinations 
of genetic variants, e.g. in OPRM1 and COMT better 
explained variability in morphine consumption than sin-
gle genetic variants [14]. Thus, one advantage of SVM is 
the possibility to include several SNPs in one analysis, 
compared to simple linear regression. However, for each 
SNP three genotypes exist. When using a binary variable 
which is necessary for SVM analysis, a dominant genetic 
model is assumed, which may not be optimal. Further-
more, the high number of SNPs included in the analysis 
may result in a lower accuracy. Additionally, if epistasis, 
which is the interaction between genes, is present, the 
effect of one SNP may be altered or masked by the effect 
of another SNP and thereby reduce the power to detect 
genetic associations. Thus, from the present study, it can-
not be excluded that some SNPs in the selected genes are 
associated with required opioid dose.
Various statistical methods (based on general linear 
models) to predict and assess data relationship exist, 
but here, a SVM approach was selected, according to 
two reviews [15, 16]. Machine learning differs from con-
ventional statistics, in that there is no predefined model 
and assumption of data normality, and each patient is 
Table 1 continued
Gene dbSNP Geno-
type
Fre-
quency
Percent-
age
Cumulative
OPRK1 rs7815824 AG 155 7.09 7.09
GG 2032 92.91 100
Total 2187 100
COMT rs2020917 CC 904 50.31 50.31
CT 744 41.4 91.71
TT 149 8.29 100
Total 1797 100
rs5993882 GG 110 5.05 5.05
GT 793 36.43 41.48
TT 1274 58.52 100
Total 2177 100
rs4646312 CC 344 15.87 15.87
CT 1032 47.6 63.47
TT 792 36.53 100
Total 2168 100
rs165722 CC 413 22.65 22.65
CT 926 50.8 73.45
TT 484 26.55 100
Total 1823 100
rs4633 CC 129 21.57 21.57
CT 307 51.34 72.91
TT 162 27.09 100
Total 598 100
rs4680 AA 623 27.9 27.9
AG 1110 49.71 77.61
GG 500 22.39 100
Total 2233 100
dbSNP single nucleotide polymorphism database identification, OPRD δ-opioid 
receptor, OPRM μ-opioid receptor, OPRK κ-opioid receptor, COMT catechol-O-
methyltransferase, A Adenine, G Guanine; C Cytosine, T Thymine
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classified at the individual level rather than the group. 
Furthermore, SVM can find non-linear relationships in 
data, and assess complex associations between several 
parameters. The latter is different from the traditional 
one-at-time approach in statistics, where relatively few 
variables can be tested. On the contrary, the SVM model 
can be over-fitted to the data and thus loose generaliz-
ability. Moreover, the method is relatively new, and many 
clinicians and researchers are not familiar with the 
method and output from the model.
Although the method of SVM presents itself with sev-
eral limitations, methodological limitations of the study 
design itself may also have had an influence on the result. 
First, as opioid dose was the primary outcome in the EPOS 
study, it was used as outcome in the present study as well. 
Here it was anticipated that opioid dose is related to opi-
oid response, i.e. high dose = less responsiveness to opioid 
analgesia, and low dose  =  high responsiveness to opioid 
analgesia, however this is only a rough estimation and 
many other factors may be important. Hence, a compos-
ite score taking pain intensity, opioid dose and side-effects 
into consideration might be a better outcome for associa-
tion analyses of opioid efficacy [17]. However, such a com-
posite score has not been developed or validated for cancer 
pain patients. In addition, only three opioid receptor genes 
were included in the analysis. Future studies should include 
more, as well as SNPs within genes other than those related 
to opioid receptor signaling, e.g. genes coding for phar-
macokinetic factors. For instance, associations between 
SNPs within the ATP-binding cassette transporter- and 
cytochrome P450 genes and opioid analgesia have been 
found in both healthy volunteer and patient studies [4, 17].
Moreover, as human genetic factors only account for 
part of the inter-individual difference in pain sensitivity, 
several cofactors may also influence opioid consump-
tion during the post-operative period. These include 
age, gender, mood, anxiety, drug–drug interactions and 
epigenetic factors. Thus, human experimental pain stud-
ies, conducted in a controlled setting, have shown to be 
of value to explore the genetic contribution to both pain 
sensitivity and analgesic responses [18].
Abbreviations
SNPs: several single nucleotide polymorphisms; EPOS: European Pharmacoge-
netic Opioid Study; SVM: support vector machine.
Authors’ contributions
PK and FS collected, analyzed and interpreted data from the EPOS study. 
AEO, DG, MG and AMD analyzed and interpreted the SVM data regarding 
associations between opioid consumption and genetic profiling. All authors 
contributed to the final manuscript. All authors read and approved the final 
manuscript.
Author details
1 Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg 
University Hospital, Aalborg, Denmark. 2 Department of Drug Design 
and Pharmacology, Faculty of Health and Medical Sciences, University 
of Copenhagen, Copenhagen, Denmark. 3 Department of Clinical Medicine, 
Aalborg University, Aalborg, Denmark. 4 Department of Clinical and Molecu-
lar Medicine, Norwegian University of Science and Technology, Trondheim, 
Norway. 5 Department of Cancer Research and Molecular Medicine, European 
Palliative Care Research Centre, Norwegian University of Science and Technol-
ogy (NTNU), Trondheim, Norway. 6 Department of Circulation and Medical 
Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, 
Norway. 7 Department of Anesthesiology and Intensive Care Medicine, St 
Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The EPOS study was conducted in accordance with the Declaration of 
Helsinki. Ethical approval was obtained from the local ethical committee in 
each participating study centre (Norway: The Regional Committee for Medical 
Research Ethics; Denmark: De Videnskabsetiske Komitéer for Københavns og 
Frederiksbergs Kommuner; Germany: Ethik-kommission an der Medizinischen 
Fakultät in Aachen; Iceland: The National Bioethics Committee of Iceland; Italy; 
Il Comitato Etico Independente, Comitato Etico dell’ Azienda-Unita’ Sanitaria 
Locale De Forli’, Comitato Etico Centrale dell’ Fondazione Salvatore Muageri; 
Lithuania: Lithuanian Bioethics Committee; Sweden: Regionala Etikprövnin-
gensnämnden i Stockholm; Switzerland: Etikkommission des Kantos St. Gallen; 
United Kingdom: The Royal Marsden Local Research Ethics Committee). Writ-
ten informed consent was obtained from each volunteer.
Funding
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 21 November 2017   Accepted: 19 January 2018
References
 1. Grosen K, Fischer IWD, Olesen AE, Drewes AM. Can quantitative 
sensory testing predict responses to analgesic treatment? Eur J Pain. 
2013;17(9):1267–80.
 2. Bruehl S, et al. Personalized medicine and opioid analgesic prescribing for 
chronic pain: opportunities and challenges. J Pain. 2013;14(2):103–13.
 3. Gram M, et al. Prediction of postoperative opioid analgesia using clinical-
experimental parameters and electroencephalography. Eur J Pain (UK). 
2017;21(2):264–77.
 4. Nielsen LM, Olesen AE, Branford R, Christrup LL, Sato H, Drewes AM. Asso-
ciation between human pain-related genotypes and variability in opioid 
analgesia: an updated review. Pain Pract. 2015;15(6):580–94.
 5. Fladvad T, Fayers P, Skorpen F, Kaasa S, Klepstad P. Lack of association 
between genetic variability and multiple pain-related outcomes in a 
large cohort of patients with advanced cancer: the European Pharmaco-
genetic Opioid Study (EPOS). BMJ Support Palliat Care. 2012;2(4):351–5.
 6. Klepstad P, et al. Influence from genetic variability on opioid use for 
cancer pain: a European genetic association study of 2294 cancer pain 
patients. Pain. 2011;152(5):1139–45.
Page 5 of 5Olesen et al. BMC Res Notes  (2018) 11:78 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 7. Gram M, Graversen C, Olesen AE, Drewes AM. Machine learning on 
encephalographic activity may predict opioid analgesia. Eur J Pain (UK). 
2015;19(10):1552–61.
 8. Smith M, Muralidharan A. Pharmacogenetics of pain and analgesia. Clin 
Genet. 2012;82(4):321–30.
 9. Kim H, et al. Genetic influence on variability in human acute experimen-
tal pain sensitivity associated with gender, ethnicity and psychological 
temperament. Pain. 2004;109(3):488–96.
 10. Graversen C, Drewes AM, Farina D. Support vector machine classification 
of multi-channel EEG traces: a new tool to analyze the brain response to 
morphine treatment,” in 2010 Annual International Conference of the IEEE 
Engineering in Medicine and Biology, 2010, pp. 992–5.
 11. Chang C-C, Lin C-J. LIBSVM. ACM Trans Intell Syst Technol. 2011;2(3):1–27.
 12. Gong Q, et al. Prognostic prediction of therapeutic response in depres-
sion using high-field MR imaging. Neuroimage. 2011;55(4):1497–503.
 13. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 
1995;20(3):273–97.
 14. De Gregori M, et al. Human genetic variability contributes to postopera-
tive morphine consumption. J Pain. 2016;17(5):628–36.
 15. Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using 
support vector machine to identify imaging biomarkers of neurologi-
cal and psychiatric disease: a critical review. Neurosci Biobehav Rev. 
2012;36(4):1140–52.
 16. Pombo N, Araújo P, Viana J. Knowledge discovery in clinical decision sup-
port systems for pain management: a systematic review. Artif Intell Med. 
2014;60(1):1–11.
 17. Silverman DG, O’connor TZ, Brull SJ. Integrated assessment of pain scores 
and rescue morphine use during studies of analgesic efficacy. Anesth 
Analg. 1993;77(1):168–70.
 18. Olesen AE, Andresen T, Staahl C, Drewes AM. Human experimental pain 
models for assessing the therapeutic efficacy of analgesic drugs. Pharma-
col Rev. 2012;64(3):722–79.
